Please ensure Javascript is enabled for purposes of website accessibility

Why The Medicines Company Acquired a Higher Price Today

By Brian Orelli, PhD - Jan 20, 2016 at 7:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Unnamed sources say the drug company is selling some or all of its assets.

What: The Medicines Company (MDCO) ended the day up 14.5% after Bloomberg reported that the drug company is exploring selling itself.

So what: Investors don't seem to know what to do with the information. The stock spiked on the news and then nearly fell back to where it started the day, only to shoot back up again, albeit slower than the morning action.

MDCO Price Chart

MDCO Price data by YCharts

The early afternoon swing could have been from Reuters confirming that The Medicine Company is up to something. The Reuters version of the story included a wrinkle that could have some, but potentially not all, of The Medicine Company's drugs being sold.

The biotech indexes started to rally around the same time, so the afternoon increase could have little to do with the potential buyout; in this market, drug companies are trading more on how investors feel about the sector as a whole than on the prospects of the individual companies.

Now what: We already knew that The Medicines Company's management is considering narrowing its focus, potentially selling assets or spinning them out into a new company. On its last earnings conference call in November, management gave a timeframe of six months to 18 months for a spinout, but noted that it could sell off its three approved hemostatic agents as well as some non-core products before then. It seems likely these reported rumors are linked to these potential sales.

On that same call, Fredric Eshelman, the company's non-executive chairman said, "The company's board of directors believes that our shares currently trade at a significant discount to the company's intrinsic value." Given that shares are lower than where they were for most of November, it seems unlikely we'll see a full sale unless the company gets an offer with an outrageous premium.

There are plenty of cases where the sum of two individual companies has resulted in higher valuations than the whole company could muster -- typically because they attract different investors -- but there are no guarantees. Buying The Medicines Company at this point is an act of faith in the ability of the drugmaker's management to extract value out of the company's assets.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Medicines Company Stock Quote
The Medicines Company
MDCO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.